1 completed, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow Cytochrome P-450 CYP2B6: new trials by email Literature Review of Cytochrome P-450 CYP2B6 trials Research Report on Cytochrome P-450 CYP2B6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Influence of Diabetes on Tramadol Pharmacokinetics Single oral dose of 100 mg racemic tramadol, CYP2D6 phenotype, CYP3A phenotype - Neuropathic Pain, Type 1 Diabetes Mellitus | Phase 4 | Completed | Universidade Estadual Paulista Júlio de Mesquita Filho | 30 | 2008-06-01 | 2014-09-23 |
Cholangiocarcinoma (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Glioma (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Neuralgia (1)
Rigel Pharmaceuticals (1) · Universidade Estadual Paulista Júlio de Mesquita Filho (1)
Brazil (1) · United States (1)